Global Antirheumatics Pharmaceutical Market Forecast 2023
Global antirheumatics market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases help increase the demand for various arthritis treatments.
Global antirheumatics market is expected to be worth USD 56.88 billion by 2023.
As per NAVADHI Market Research, global antirheumatics pharmaceutical market will we worth USD 56.88 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
Antirheumatics had the second largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain it’s position even in 2023.
As per industry sources, about 1.3 million people suffer from rheumatoid arthritis (RA) in United States, 2.9 million in European Union and 1.4 million in Japan and most of the patients are women. With the increasing lifespans due to improved healthcare facilities more and more people are prone to rheumatoid arthritis.
This growth in antirheumatics market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antirheumatics industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics and cell therapies has attracted investments in the industry which is fueling this growth.
On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antirheumatics industry. Antirheumatics companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global antirheumatics market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Competition from generic manufacturers is also a concern for major brands. For example – Cipla in 2013 launched the biosimilar of etanercept under brand name Etacept for the treatment of rheumatic disorders which was cheaper alternative of Amgen and Pfizer's hugely successful Enbrel brand.
On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 7th based on their FY 2018 antirheumatics revenue announced their plan to acquire Celgene Corporation which was ranked 10th in the world for antirheumatics revenue. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Pfizer for 3rd spot in global antirheumatics revenue.
Spanning over 267 pages and 180 exhibits, “Global Antirheumatics Pharmaceutical Market Forecast 2023” report provides in-depth analysis for the global antirheumatics pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.
This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antirheumatics market namely: AbbVie Inc., Amgen Inc., Pfizer Inc., Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Inc., UCB S.A. and Eli Lilly and Company
Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report
This report provides detailed information about Global antirheumatics market including future market forecasts till 2023.
This report identifies the need for focusing on global antirheumatics market.
The report identifies the growth drivers and inhibitors for global antirheumatics market.
The report identifies various risks associated with global antirheumatics market.
This report has detailed profiles of 10 key players in Global antirheumatics market covering their business strategy, financial performance, future forecasts and SWOT analysis.
This report provides competitive landscape among top 10 key companies in Global antirheumatics market.
This report provides Porter’s Five Forces analysis for Global antirheumatics market.
This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antirheumatics market.
This report provides information about current and future trends for Global antirheumatics market.
Global antirheumatics market is expected to be worth USD 56.88 billion by 2023.
As per NAVADHI Market Research, global antirheumatics pharmaceutical market will we worth USD 56.88 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
Antirheumatics had the second largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain it’s position even in 2023.
As per industry sources, about 1.3 million people suffer from rheumatoid arthritis (RA) in United States, 2.9 million in European Union and 1.4 million in Japan and most of the patients are women. With the increasing lifespans due to improved healthcare facilities more and more people are prone to rheumatoid arthritis.
This growth in antirheumatics market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antirheumatics industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics and cell therapies has attracted investments in the industry which is fueling this growth.
On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antirheumatics industry. Antirheumatics companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global antirheumatics market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Competition from generic manufacturers is also a concern for major brands. For example – Cipla in 2013 launched the biosimilar of etanercept under brand name Etacept for the treatment of rheumatic disorders which was cheaper alternative of Amgen and Pfizer's hugely successful Enbrel brand.
On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 7th based on their FY 2018 antirheumatics revenue announced their plan to acquire Celgene Corporation which was ranked 10th in the world for antirheumatics revenue. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Pfizer for 3rd spot in global antirheumatics revenue.
Spanning over 267 pages and 180 exhibits, “Global Antirheumatics Pharmaceutical Market Forecast 2023” report provides in-depth analysis for the global antirheumatics pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.
This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antirheumatics market namely: AbbVie Inc., Amgen Inc., Pfizer Inc., Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Inc., UCB S.A. and Eli Lilly and Company
Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report
This report provides detailed information about Global antirheumatics market including future market forecasts till 2023.
This report identifies the need for focusing on global antirheumatics market.
The report identifies the growth drivers and inhibitors for global antirheumatics market.
The report identifies various risks associated with global antirheumatics market.
This report has detailed profiles of 10 key players in Global antirheumatics market covering their business strategy, financial performance, future forecasts and SWOT analysis.
This report provides competitive landscape among top 10 key companies in Global antirheumatics market.
This report provides Porter’s Five Forces analysis for Global antirheumatics market.
This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antirheumatics market.
This report provides information about current and future trends for Global antirheumatics market.
1. EXECUTIVE SUMMARY
Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report
Research Methodology
2. INTRODUCTION OF PHARMACEUTICALS INDUSTRY
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Global Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR GLOBAL ANTIRHEUMATICS MARKET
Rising & Ageing Global Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR GLOBAL ANTIRHEUMATICS MARKET 2023
4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
4.1.1 Forecast for Global Antirheumatics Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL ANTIRHEUMATICS MARKET
6. RISKS ASSOCIATED WITH GLOBAL ANTIRHEUMATICS MARKET
7. INDUSTRY ASSOCIATIONS RELATED TO GLOBAL PHARMACEUTICALS MARKET
7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association of the British Pharmaceutical Industry (ABPI)
7.5 Japan Pharmaceutical Manufacturers Association (JPMA)
7.6 Indian Drug Manufacturers' Association (IDMA)
8. PROFILE OF KEY PLAYERS IN GLOBAL ANTIRHEUMATICS MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Novartis AG
8.2.1 Company Profile
8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Novartis AG: Financial Performance
8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Novartis AG: Business Strategy
8.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.3 Johnson & Johnson
8.3.1 Company Profile
8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Johnson & Johnson Financial Performance
8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.3.4 Johnson & Johnson: Business Strategy
8.3.4.1 Product Level Business Strategy
8.3.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.3.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.4 Amgen Inc.
8.4.1 Company Profile
8.4.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 Amgen Inc: Financial Performance
8.4.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.4.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.4.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.4.4 Amgen Inc.: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
8.5 Roche Holding AG
8.5.1 Company Profile
8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Roche Holding AG: Financial Performance
8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.5.4 Roche Holding AG: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.5.6 Key Customers of Roche Holding AG
8.6 Merck & Co., Inc.
8.6.1 Company Profile
8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Merck & Co., Inc.: Financial Performance
8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Merck & Co., Inc.: Business Strategy
8.6.4.1 Product Level Strategy
8.6.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7 UCB S.A.
8.7.1 Company Profile
8.7.2 UCB S.A. in Pharmaceutical Manufacturing Value Chain
8.7.3 UCB S.A. Financial Performance
8.7.3.1 UCB S.A.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.7.3.2 UCB S.A.: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 UCB S.A.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 UCB S.A.: Business Strategy
8.7.4.1 Product Level Business Strategy
8.7.6 SWOT Analysis of UCB S.A.
Strengths
Weaknesses
Opportunities
Threats
8.8 AbbVie Inc.
8.8.1 Company Profile
8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 AbbVie Inc.: Financial Performance
8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.8.4 AbbVie Inc.: Business Strategy
8.8.4.1 Product Level Strategy
8.8.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Eli Lilly and Company
8.9.1 Company Profile
8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Eli Lilly: Financial Performance
8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.9.4 Eli Lilly: Business Strategy
8.9.4.1 Product Level Strategy
8.9.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
8.10 Bristol-Myers Squib Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN GLOBAL ANTIRHEUMATICS MARKET
9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue
9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue
9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue
9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure
9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Earning Per Share (EPS)
9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast
9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatic Product Revenues
10. ANALYSIS OF GLOBAL ANTIRHEUMATICS MARKET
10.1 Porter’s Five Forces Analysis of Global Antirheumatics Market
10.2 SWOT Analysis of Global Antirheumatics Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN GLOBAL ANTIRHEUMATICS MARKET
Notes
Company Information
Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report
Research Methodology
2. INTRODUCTION OF PHARMACEUTICALS INDUSTRY
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Global Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR GLOBAL ANTIRHEUMATICS MARKET
Rising & Ageing Global Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR GLOBAL ANTIRHEUMATICS MARKET 2023
4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
4.1.1 Forecast for Global Antirheumatics Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL ANTIRHEUMATICS MARKET
6. RISKS ASSOCIATED WITH GLOBAL ANTIRHEUMATICS MARKET
7. INDUSTRY ASSOCIATIONS RELATED TO GLOBAL PHARMACEUTICALS MARKET
7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association of the British Pharmaceutical Industry (ABPI)
7.5 Japan Pharmaceutical Manufacturers Association (JPMA)
7.6 Indian Drug Manufacturers' Association (IDMA)
8. PROFILE OF KEY PLAYERS IN GLOBAL ANTIRHEUMATICS MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Novartis AG
8.2.1 Company Profile
8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Novartis AG: Financial Performance
8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Novartis AG: Business Strategy
8.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.3 Johnson & Johnson
8.3.1 Company Profile
8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Johnson & Johnson Financial Performance
8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.3.4 Johnson & Johnson: Business Strategy
8.3.4.1 Product Level Business Strategy
8.3.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.3.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.4 Amgen Inc.
8.4.1 Company Profile
8.4.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 Amgen Inc: Financial Performance
8.4.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.4.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.4.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.4.4 Amgen Inc.: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
8.5 Roche Holding AG
8.5.1 Company Profile
8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Roche Holding AG: Financial Performance
8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.5.4 Roche Holding AG: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.5.6 Key Customers of Roche Holding AG
8.6 Merck & Co., Inc.
8.6.1 Company Profile
8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Merck & Co., Inc.: Financial Performance
8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Merck & Co., Inc.: Business Strategy
8.6.4.1 Product Level Strategy
8.6.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7 UCB S.A.
8.7.1 Company Profile
8.7.2 UCB S.A. in Pharmaceutical Manufacturing Value Chain
8.7.3 UCB S.A. Financial Performance
8.7.3.1 UCB S.A.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.7.3.2 UCB S.A.: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 UCB S.A.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 UCB S.A.: Business Strategy
8.7.4.1 Product Level Business Strategy
8.7.6 SWOT Analysis of UCB S.A.
Strengths
Weaknesses
Opportunities
Threats
8.8 AbbVie Inc.
8.8.1 Company Profile
8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 AbbVie Inc.: Financial Performance
8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.8.4 AbbVie Inc.: Business Strategy
8.8.4.1 Product Level Strategy
8.8.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Eli Lilly and Company
8.9.1 Company Profile
8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Eli Lilly: Financial Performance
8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.9.4 Eli Lilly: Business Strategy
8.9.4.1 Product Level Strategy
8.9.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
8.10 Bristol-Myers Squib Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN GLOBAL ANTIRHEUMATICS MARKET
9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue
9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue
9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue
9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure
9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Earning Per Share (EPS)
9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast
9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatic Product Revenues
10. ANALYSIS OF GLOBAL ANTIRHEUMATICS MARKET
10.1 Porter’s Five Forces Analysis of Global Antirheumatics Market
10.2 SWOT Analysis of Global Antirheumatics Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN GLOBAL ANTIRHEUMATICS MARKET
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
Exhibit 4.2 Forecast for Global Antirheumatics Pharmaceutical Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for Global Antirheumatics Pharmaceutical Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of EFPIA
Exhibit 7.2 Contact details of EFPIA
Exhibit 7.3 List of EFPIA Members
Exhibit 7.4 Key Information of IFPMA
Exhibit 7.5 Contact details of IFPMA
Exhibit 7.6 List of IFPMA Members
Exhibit 7.7 Key Information of PhRMA
Exhibit 7.8 Contact details of PhRMA
Exhibit 7.9 List of PhRMA Members
Exhibit 7.10 Key information of ABPI
Exhibit 7.11 Contact details of ABPI
Exhibit 7.12 List of ABPI Members
Exhibit 7.13 Key Information of JPMA
Exhibit 7.13 Key Information of JPMA
Exhibit 7.15 List of JPMA Members
Exhibit 7.16 Key information of IDMA
Exhibit 7.17 Contact details of IDMA
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Novartis AG
Exhibit 8.11 Contact Information of Novartis AG
Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.22 SWOT Analysis of Novartis AG
Exhibit 8.23 Key Information of Johnson & Johnson
Exhibit 8.24 Contact information of Johnson & Johnson
Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.32 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.34 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.35 SWOT Analysis of Johnson & Johnson
Exhibit 8.36 Key information of Amgen Inc.
Exhibit 8.37 Contact details of Amgen Inc.
Exhibit 8.38 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 8.39 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 8.40 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 8.41 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.42 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.43 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.44 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.45 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.46 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.47 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.48 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.49 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.50 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.51 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.52 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 8.53 SWOT Analysis of Amgen Inc.
Exhibit 8.54 Key Information of Roche Holding AG
Exhibit 8.56 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.57 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.58 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.59 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.60 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.61 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.62 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.63 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.64 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.65 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.66 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.67 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.68 SWOT Analysis of Roche Holding AG
Exhibit 8.69 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.70 Key Information of Merck & Co.
Exhibit 8.71 Contact Information of Merck & Co.
Exhibit 8.72 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.73 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.74 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.75 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.76 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.77 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.78 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.79 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.80 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.81 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.82 Key Information of UCB S.A.
Exhibit 8.83 Contact information of UCB S.A.
Exhibit 8.84 UCB S.A. in Pharmaceutical Manufacturing Value Chain
Exhibit 8.85 Revenue of UCB S.A. FY 2013-FY 2019 (in USD billion)
Exhibit 8.86 Revenue Growth of UCB S.A. FY 2014-FY 2019 (in %)
Exhibit 8.87 Geography-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)
Exhibit 8.88 United States Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)
Exhibit 8.89 United States Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.90 Europe Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)
Exhibit 8.91 Europe Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.92 Rest of World Revenue of UCB S.A. FY 2014-FY 2018 (in USD billion)
Exhibit 8.93 Rest of World Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.94 Therapy Area-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)
Exhibit 8.95 Therapy Area-Wise Revenue of UCB S.A. FY 2018 (in USD billion)
Exhibit 8.96 UCB S.A. Product Pipeline
Exhibit 8.97 SWOT Analysis of UCB S.A.
Exhibit 8.98 Key information of AbbVie Inc.
Exhibit 8.99 Contact Information of AbbVie. Inc.
Exhibit 8.100 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.101 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.102 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.103 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.104 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.105 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.106 SWOT Analysis of AbbVie Inc.
Exhibit 8.107 Key information of Eli Lilly
Exhibit 8.108 Contact Information Eli Lilly
Exhibit 8.109 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.110 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.111 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 8.112 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.113 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.114 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.115 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.116 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.117 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.118 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.119 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.120 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.121 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.122 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.123 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.124 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.125 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.126 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 8.127 SWOT Analysis of Eli Lilly and Company
Exhibit 8.128 Key Information of Bristol-Myers Squib Company
Exhibit 8.129 Contact Information of Bristol-Myers Squib Company
Exhibit 8.130 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.131 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.132 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.133 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.135 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.136 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.137 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.138 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.139 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.140 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.141 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.142 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.143 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Product-Wise Antirheumatics Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for Global Antirheumatics Pharmaceutical Market
Exhibit 10.2 SWOT Analysis for Global Antirheumatics Pharmaceutical Market
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
Exhibit 4.2 Forecast for Global Antirheumatics Pharmaceutical Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for Global Antirheumatics Pharmaceutical Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of EFPIA
Exhibit 7.2 Contact details of EFPIA
Exhibit 7.3 List of EFPIA Members
Exhibit 7.4 Key Information of IFPMA
Exhibit 7.5 Contact details of IFPMA
Exhibit 7.6 List of IFPMA Members
Exhibit 7.7 Key Information of PhRMA
Exhibit 7.8 Contact details of PhRMA
Exhibit 7.9 List of PhRMA Members
Exhibit 7.10 Key information of ABPI
Exhibit 7.11 Contact details of ABPI
Exhibit 7.12 List of ABPI Members
Exhibit 7.13 Key Information of JPMA
Exhibit 7.13 Key Information of JPMA
Exhibit 7.15 List of JPMA Members
Exhibit 7.16 Key information of IDMA
Exhibit 7.17 Contact details of IDMA
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Novartis AG
Exhibit 8.11 Contact Information of Novartis AG
Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.22 SWOT Analysis of Novartis AG
Exhibit 8.23 Key Information of Johnson & Johnson
Exhibit 8.24 Contact information of Johnson & Johnson
Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.32 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.34 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.35 SWOT Analysis of Johnson & Johnson
Exhibit 8.36 Key information of Amgen Inc.
Exhibit 8.37 Contact details of Amgen Inc.
Exhibit 8.38 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 8.39 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 8.40 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 8.41 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.42 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.43 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.44 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.45 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.46 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.47 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.48 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.49 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.50 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.51 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.52 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 8.53 SWOT Analysis of Amgen Inc.
Exhibit 8.54 Key Information of Roche Holding AG
Exhibit 8.56 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.57 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.58 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.59 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.60 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.61 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.62 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.63 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.64 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.65 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.66 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.67 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.68 SWOT Analysis of Roche Holding AG
Exhibit 8.69 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.70 Key Information of Merck & Co.
Exhibit 8.71 Contact Information of Merck & Co.
Exhibit 8.72 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.73 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.74 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.75 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.76 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.77 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.78 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.79 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.80 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.81 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.82 Key Information of UCB S.A.
Exhibit 8.83 Contact information of UCB S.A.
Exhibit 8.84 UCB S.A. in Pharmaceutical Manufacturing Value Chain
Exhibit 8.85 Revenue of UCB S.A. FY 2013-FY 2019 (in USD billion)
Exhibit 8.86 Revenue Growth of UCB S.A. FY 2014-FY 2019 (in %)
Exhibit 8.87 Geography-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)
Exhibit 8.88 United States Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)
Exhibit 8.89 United States Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.90 Europe Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)
Exhibit 8.91 Europe Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.92 Rest of World Revenue of UCB S.A. FY 2014-FY 2018 (in USD billion)
Exhibit 8.93 Rest of World Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)
Exhibit 8.94 Therapy Area-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)
Exhibit 8.95 Therapy Area-Wise Revenue of UCB S.A. FY 2018 (in USD billion)
Exhibit 8.96 UCB S.A. Product Pipeline
Exhibit 8.97 SWOT Analysis of UCB S.A.
Exhibit 8.98 Key information of AbbVie Inc.
Exhibit 8.99 Contact Information of AbbVie. Inc.
Exhibit 8.100 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.101 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.102 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.103 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.104 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.105 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.106 SWOT Analysis of AbbVie Inc.
Exhibit 8.107 Key information of Eli Lilly
Exhibit 8.108 Contact Information Eli Lilly
Exhibit 8.109 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.110 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.111 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 8.112 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.113 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.114 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.115 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.116 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.117 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.118 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.119 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.120 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.121 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.122 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.123 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.124 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.125 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.126 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 8.127 SWOT Analysis of Eli Lilly and Company
Exhibit 8.128 Key Information of Bristol-Myers Squib Company
Exhibit 8.129 Contact Information of Bristol-Myers Squib Company
Exhibit 8.130 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.131 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.132 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.133 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.135 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.136 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.137 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.138 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.139 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.140 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.141 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.142 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.143 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Product-Wise Antirheumatics Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for Global Antirheumatics Pharmaceutical Market
Exhibit 10.2 SWOT Analysis for Global Antirheumatics Pharmaceutical Market
